ABL1

Biomarkers

ABL1 is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
ABL1 p.T315I	Somatic Variant	3	5
BCR::ABL1	Rearrangement	1	1
BCR::ABL1	Rearrangement	14	36

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
FDA (1) HC (1)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
FDA (1) HC (1)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib
FDA (1)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
FDA (2)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
FDA (2) HC (2)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
FDA (3)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
FDA (3)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib
FDA (2)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib
FDA (2) HC (2)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib
FDA (2)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib
FDA (2) HC (2)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib
FDA (3)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
FDA (3)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib
FDA (1)	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (2)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib